This trial is evaluating whether Perampanel will improve 1 primary outcome and 1 secondary outcome in patients with Amyotrophic Lateral Sclerosis. Measurement will happen over the course of 9 months.
This trial requires 60 total participants across 2 different treatment groups
This trial involves 2 different treatments. Perampanel is the primary treatment being studied. Participants will all receive the same treatment. Some patients will receive a placebo treatment. The treatments being tested are not being studied for commercial purposes.
"The American Cancer Society estimates approximately 20,000 new cases of non-Hodgkin's lymphoma will be diagnosed in 2019 and 5,000 deaths will be attributed to the disease. In 2018, about 36,000 Americans will get the disease. By 2050, about 10 million people will have the disease. The disease is the most common cause of death among men and women under 50 years of age." - Anonymous Online Contributor
"Several options to treat ALS are available, depending on the progress and severity of the disease and patient preferences. One such option is riluzole, a drugs under development that is used to halt and reverse nerve cell death. It is not approved by US health care providers as a treatment for ALS. A more common treatment for ALS is a multidisciplinary approach that aims to rehabilitate, maintain quality of life, and minimize symptoms. The current US Food and Drug Administration-approved ALS clinical trials provide this type of approach. Because ALS is a genetic disorder, many patients with familial ALS develop certain symptoms more rapidly." - Anonymous Online Contributor
"ALS was an extremely heterogeneous condition presenting, on average, with mild weakness of proximal muscles in the early stages of the disease. The disease was slowly progressive in the vast majority of cases with the progression being rapid in a minority of cases. The pattern of clinical disease progression was, on average, that of a slowly progressive disease similar to, and possibly even more slowly progressive than, amyotrophic lateral sclerosis. No clinically relevant difference from the average natural course of ALS was observed in any of the markers or scores studied; however, biomarkers may serve as potential biomarkers of disease progression. The pattern and distribution of age of onset indicated the same picture of prognosis as the pattern of progression in ALS. [Power](http://www." - Anonymous Online Contributor
"Muscle wasting, weakness, increased resistance, and dysphagia in amyotrophic lateral sclerosis are key signs of this disease. The respiratory system is often involved (bronchiectasis), as well as the gastrointestinal system (gastric outlet- obstruction or fistula). The central nervous system can also experience the neurological involvement and psychiatric disorders. The liver and kidneys are not always involved." - Anonymous Online Contributor
"Many different genetic and environmental factors can cause ALS. Symptoms of the disorder include muscle weakness, numbness and changes in sense of touch. It is unclear why ALS affects only certain nerve cells in the motor system. Because ALS can occur sporadically and seems to be associated with an abnormal buildup of protein clumps called neurofibrillary tangles in the brain, experts suspect that the risk of ALS may be increased by environmental factors such as pollution or viruses.\nquestion: Neurological and cardiac signs of diabetes mellitus: is there an association with the duration of diabetes? answer: There are no specific clinical signs suggestive of carotid artery disease that can be identified in patients with a history of diabetes." - Anonymous Online Contributor
"ALS was associated with a significantly higher rate of early death after diagnosis in comparison with the general population, independent of gender. The cause of the excess of early death needs to be elucidated." - Anonymous Online Contributor
"This article contains the latest research for amyotrophic lateral sclerosis on the subject of drug use as the disease advances. It is important to know that the disease will advance and the research presented here will not always help." - Anonymous Online Contributor
"There was no evidence that first-degree family members of patients with ALS demonstrate increased incidence of disease or slower rates of disability, compared with the general population." - Anonymous Online Contributor
"In 2013, there were 14,345 new diagnoses of ALS in the United States and about 1 in 4 would die from ALS by age 85. Although there are more women diagnosed with ALS, the number of men who die from the disease seems to be higher. There are also many variations among the different age groups. In fact, there is a higher chance of men dying from ALS, especially in the 55-74 age group, rather than women. If a person does have ALS, it must be very early in life, since the rate of ALS decreases with age. As of 2015, there are no treatments that have halted the degradation of the motor muscles." - Anonymous Online Contributor
"Perampanel was used frequently in combination with either an ABA or a second medication. There is no published evidence suggesting a clinically important interaction, and the FDA approves perampanel for treating partial-onset and tonic-clonic seizures in adults with either a single or a combination medications as a single therapeutic agent. The combination of perampanel with an ABA is contraindicated, as there is no evidence to support such an additive effect." - Anonymous Online Contributor
"Muscle weakness, muscle wasting and the degeneration of motor units are the main causes of this disease. However, the mechanism of its progression is debated." - Anonymous Online Contributor
"In both patients with and without depressive symptoms, perampanel had positive and sustained antipsychotic properties in the short term that normalized psychotic symptoms and significantly improved quality of life. Future studies should prospectively characterize the long-term effects of perampanel." - Anonymous Online Contributor